Psoriasis Treatment Selection: Route of Administration and Comparative Effectiveness

Updates in the therapeutic landscape for psoariasis in the last decade have raised the bar for treatment standards.

Bruce Strober, MD, PhD, examines patient preference for oral versus injectable therapy.

Bruce Strober, MD, PhD, compares agents within the IL-23 inhibitor class on dosing schedule and joint outcome data, and explains why long-term drug survival has become a central consideration in biologic selection for psoriasis.

Bruce Strober, MD, PhD, introduces a practical framework for determining when differences in efficacy between psoriasis treatments are clinically meaningful.

Bruce Strober, MD, PhD, details a principled approach to sequencing psoriasis therapies based on mechanism and response pattern.